VectorY Therapeutics

Executive Summary

VectorY Therapeutics is a preclinical-stage biotechnology company developing novel vectorized antibody therapies for severe neurodegenerative diseases. The company's proprietary platform combines adeno-associated virus (AAV) gene therapy with antibody engineering to achieve sustained, CNS-targeted expression of therapeutic antibodies from a single administration. This approach addresses key challenges in treating disorders like ALS and Huntington's disease, including blood-brain barrier penetration and the need for repeated dosing. Founded in 2020 and headquartered in Amsterdam, the company has raised $129 million to date, primarily through a Series A round, and is advancing its pipeline toward clinical development. VectorY's lead programs target ALS and Huntington's disease, both areas with high unmet medical need. The company has generated preclinical proof-of-concept data demonstrating durable antibody expression and disease modification in animal models. With its strong financial backing and innovative platform, VectorY is well-positioned to begin clinical testing. Key upcoming milestones include the selection of a development candidate for its ALS program and potential IND-enabling studies. While still in early stages, the company's technology has the potential to transform the treatment landscape for neurodegenerative conditions by providing long-lasting, single-dose therapies.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Efficacy Data Readout for ALS Program40% success
• 2027IND Filing for Lead Huntington's Disease Candidate30% success
• Q3 2026Series B Financing to Support Clinical Development70% success